Table 3.
Reported results of anti-PD-1/PD-L1 in thymic malignancies
| Thymomas |
Thymic carcinoma |
Grade ≥3 adverse events |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | Response |
Stable disease |
Outcome | n | Response |
Stable disease |
Outcome | Rate |
Events | |
| n (%) | n (%) | n (%) | n (%) | n (%) | ||||||
| Single case reports | ||||||||||
| Zander et al. [48] | 1 | 1 (100%) | 0 (0%) | Response at 2 months | 1 (100%) | Cutaneous toxicity involving skin, mouth, esophagus, uvea and glans | ||||
| Isshiki et al. [49] | 1 | 1 (100%) | Response at 9 weeks | 0 (0%) | ||||||
| Uchida et al. [50] | 4 | 3 (75%) | 1 (25%) | Response at 10, 12 and 16 weeks | 1 (25%) | General malaise | ||||
| Clinical trials | ||||||||||
| Giaccone et al. [51] | 40 | 9 (23%) | 21 (53%) | mPFS: 4.2 months mOS: 24.9 months |
6 (15%) | Myositis, myocarditis, pancreatitis, hepatitis and pemphigoid | ||||
| Cho et al. [52] | 7 | 2 (29%) | 5 (72%) | mPFS: 6.1 months | 26 | 6 (23%) | 13 (50%) | mPFS: 6.1 months | 9 (27%) | Myositis, myocarditis, myasthenia and hepatitis |
| Katzuya et al. [53] | 15 | 0 (0%) | 11 (73%) | mPFS: 3.8 months | 2 (13%) | Elevated transaminases and adrenal insufficiency | ||||
| Rajan et al. [54] | 7 | 4 (57%) | 2 (28%) | NR | 1 | 0 (0%) | 1 (100%) | NR | 5 (71%) | Myositis |
mPFS, median progression-free survival; mOS, median overall survival; NR, not reached.